title: Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin.
abstract: OBJECTIVE
  Iridocyclitis has been identified as a dosage-dependent side effect in patients with the acquired immunodeficiency syndrome (AIDS) who are treated for Mycobacterium avium complex (MAC) infection with systemic rifabutin. We reviewed cases of acute hypopyon uveitis occurring in patients with AIDS to establish whether there was an association.
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  Outpatient clinic and inpatient hospital-based ophthalmology referral practice and infectious disease specialty service.
  
  
  METHODS
  Seven patients with AIDS, aged 10 to 40 years, presenting with acute unilateral hypopyon mimicking infectious endophthalmitis.
  
  
  METHODS
  Findings from complete ophthalmological evaluation and ancillary laboratory testing.
  
  
  RESULTS
  At the time of presentation, all seven patients were receiving treatment for MAC infection with rifabutin (dosage range, 300 to 600 mg/d) and clarithromycin. Results of microbiological investigations in five patients were negative. Iridocyclitis became bilateral in all seven patients, and hypopyon developed in the contralateral eye in five of seven patients. Hypopyon resolved rapidly with intensive topical corticosteroid therapy. Residual inflammation responded to topical corticosteroids with or without reduction of the rifabutin dosage.
  
  
  CONCLUSIONS
  Concomitant use of rifabutin, clarithromycin, and fluconazole may precipitate hypopyon uveitis in patients with AIDS being treated for MAC infection.
authors.affiliation: Department of Ophthalmology, Scheie Eye Institute, Philadelphia.
authors.forename: B R
authors.initials: BR
authors.lastname: Saran
authors.forename: A M
authors.initials: AM
authors.lastname: Maguire
authors.forename: C
authors.initials: C
authors.lastname: Nichols
authors.forename: I
authors.initials: I
authors.lastname: Frank
authors.forename: R W
authors.initials: RW
authors.lastname: Hertle
authors.forename: A J
authors.initials: AJ
authors.lastname: Brucker
authors.forename: S
authors.initials: S
authors.lastname: Goldman
authors.forename: M
authors.initials: M
authors.lastname: Brown
authors.forename: B
authors.initials: B
authors.lastname: Van Uitert
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002648:Child; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D015863:Iridocyclitis / Q000139:chemically induced / Q000188:drug therapy; D008297:Male; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy*; D012189:Retrospective Studies; D017828:Rifabutin / Q000009:adverse effects* / Q000627:therapeutic use; D013492:Suppuration / Q000139:chemically induced / Q000188:drug therapy; D014606:Uveitis, Anterior / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D017828:Rifabutin; D017291:Clarithromycin